TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35742702
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive non-surgical periodontal therapy (MINST)
Study: 35742702
Drug: Conventional non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-surgical periodontal therapy (CNST)
Study: 32068914
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg)
Study: 35831874
Drug: Fluralaner (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner (oral dose)
Study: 32946590
Drug: XBS +
Normalized name: Xylometazoline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: XBS + 10 × 10^6 PDL-MSCs/100 mg
Study: 35534312
Drug: Intradermal fractional-dose
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with dmLT
Study: 35534312
Drug: Fractionated dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated dose of intradermal IPV without dmLT
Study: 32865597
Drug: Dulaglutide (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (weekly for 24 weeks)
Study: 33731569
Drug: Calcium hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxylapatite with lidocaine (3 mL total, 1 to 2 syringes)
Study: 34156873
Drug: In-clinic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic therapy
Study: 34605319
Drug: Ofatumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (20 mg every 4 weeks, subcutaneous via autoinjector)
Study: 34605319
Drug: Ofatumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (20 mg every 4 weeks, subcutaneous via PFS)
Study: 34605319
Drug: Ofatumumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (both administration methods)
Study: 32435011
Drug: Dual lipid‐lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual lipid‐lowering therapy (DLLT) with ezetimibe and atorvastatin
Study: 35654052
Drug: Ibrutinib plus
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib plus venetoclax (ibrutinib: 420 mg once daily; venetoclax: weekly ramp-up from 20 mg to 400 mg once daily)
Study: 35654052
Drug: Treatment cessation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment cessation
Study: 35654052
Drug: Ibrutinib monotherapy
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib monotherapy (for patients not randomly assigned)
Study: 32019598
Drug: Subcutaneous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous paracetamol
Study: 35767384
Drug: Remestemcel-L (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remestemcel-L (150 million MSCs)
Study: 33368307
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks
Study: 33368307
Drug: Tezepelumab doses
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab doses up to 280 mg every 2 weeks
Study: 36091030
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg qw
Study: 36091030
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (etanercept + celecoxib)
Study: 35766128
Drug: Nemolizumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 0.5 mg/kg SC
Study: 34196132
Drug: Oral busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral busulfan vs. intravenous busulfan
Study: 32266380
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin once daily
Study: 34962561
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for aspirin
Study: 34962561
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ω-3 fatty acids once daily
Study: 35265304
Drug: Capecitabine sequential
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine sequential treatment for 4 cycles
Study: 35265304
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sequential treatment)
Study: 32100452
Drug: Sequential boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy (fluorouracil 600 mg/m2 days 1-3 and cisplatin 25 mg/m2 days 1-3, every 4 weeks for 4 cycles)
Study: 32100452
Drug: Sequential boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy
Study: 35028170
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract cream
Study: 33046528
Drug: laryngeal mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: laryngeal mask airway and i-gel
Study: 33175143
Drug: Nomogram including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nomogram including mixed histological types, chemotherapy, and primary site surgery as factors.
Study: 35946018
Drug: Preanesthetic fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preanesthetic fluid loading with Ringer's lactate (20 mL/kg over 30 minutes)
Study: 35946018
Drug: No preloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preloading (2 mL/kg/h maintenance)
Study: 32805028
Drug: Avocado consumption
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado consumption (175 g for men; 140 g for women) once daily for 12 weeks
Study: 35524695
Drug: Daily fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fortified balanced energy-protein supplement and an iron-folic acid (IFA) tablet
Study: 35524695
Drug: IFA tablet
Normalized name: immune globulin intravenous (human) - ifas Injection [Panzyga]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFA tablet only
Study: 33523106
Drug: AA:DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA:DHA supplementation (100 mg/kg/d of AA and 50 mg/kg/d of DHA)
Study: 33389189
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg 2 hours before surgery
Study: 33389189
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 60 mL 0.25% levobupivacaine after general anesthesia
Study: 33389189
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg 2 hours before surgery and 50 mg rectal diclofenac sodium on recovery from general anesthesia
Study: 35869503
Drug: automated, theory‐informed
Approvals — FDA: no, EMA: no, PMDA: no
Description: automated, theory‐informed text messages daily for 12 months plus endowment incentives linked to verified weight loss targets at 3, 6 and 12 months
Study: 34656640
Drug: Cholecalciferol 50,000
Normalized name: CHOLECALCIFEROL 50,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50,000 U weekly for 8 weeks followed by 10,000 U weekly for 44 weeks
Study: 34444963
Drug: 688 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 688 mg/day palmiteolate (omega-7 fatty acid supplementation)
Study: 35104737
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil hydrochloride (test formulation)
Study: 35104737
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil hydrochloride (reference formulation)
Study: 35001501
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 25 mg tablet once daily, switched from Efavirenz (EFV) plus two NRTIs for ≥3 months
Study: 35001501
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 25 mg tablet once daily
Study: 34913149
Drug: Jiuwei Zhuhuang
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jiuwei Zhuhuang Powder (JWZH) 1 to 1.5 g, twice to thrice daily for 5 days
Study: 34913149
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily for 5 days)
Study: 34913149
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules)
Study: 33813585
Drug: High-concentration phospholipid
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration phospholipid eye spray (Tears Again)
Study: 33813585
Drug: Low-concentration phospholipid
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration phospholipid eye spray (Ocuvers)
Study: 32739652
Drug: Clopidogrel monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel monotherapy for 9 months
Study: 32739652
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel for 9 months followed by aspirin monotherapy for 3 months
Study: 34044526
Drug: 5-fluorouracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil at 0.5 mg/mL combined with triamcinolone
Study: 34044526
Drug: 5-fluorouracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil at 5.0 mg/mL combined with triamcinolone
Study: 34044526
Drug: 5-fluorouracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil at 12.5 mg/mL combined with triamcinolone
Study: 33121503
Drug: FTC‐TDF or
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC‐TDF or FTC‐TAF (over 1 or 2 days, with final dose given either 6 or 20 hours prior to surgery)
Study: 33259621
Drug: Multistrategic, community-wide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistrategic, community-wide interventions using social marketing techniques and network intervention (e.g., word of mouth) over 5 years
Study: 35556389
Drug: 2-week lithium
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week lithium treatment (40 mmol/kg/food)
Study: 35556389
Drug: 4-week lithium
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week lithium treatment (40 mmol/kg/food)
Study: 33007353
Drug: Patiromer (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (starting doses ranged from 8.4 to 33.6 g/day)
Study: 33949680
Drug: Written communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written communication via leaflet with visual aids (L-VA)
Study: 33949680
Drug: Written communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written communication via leaflet with no visual aids (L-NVA)
Study: 35143607
Drug: REST intervention
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: REST intervention (occupational therapist‐led cognitive‐behavioral therapy for insomnia)
Study: 34211988
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer lamp monotherapy
Study: 34211988
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 308-nm excimer lamp and 10% liquor carbonis detergens
Study: 33414533
Drug: Systemic mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic mycophenolate mofetil (MMF) 1 g orally twice daily for the first 6 months, then 1 g daily for the next 6 months, plus corticosteroids
Study: 33414533
Drug: Topical 0.03%
Normalized name: tacrolimus topical 0.03% topical ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.03% tacrolimus four times a day for 12 months, plus corticosteroids
Study: 35543937
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with regular treatment and swallowing function training
Study: 35543937
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular treatment and swallowing function training only)
Study: 32698033
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic ointment
Study: 32698033
Drug: Placebo (mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mineral oil and petrolatum‐based) ointment
Study: 34002252
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks
Study: 36239756
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with alendronate for 120 weeks
Study: 35974359
Drug: Standard antipyretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antipyretic treatment from the participating hospital.
Study: 33221636
Drug: Standardized intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized intervention group (SIG) - brief perioperative smoking cessation intervention with nicotine patch therapy for 8 weeks
Study: 35341647
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD, 5x10^10 viral particles)
Study: 35341647
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD, 2.5x10^10 viral particles)
Study: 33780274
Drug: Alpelisib 300
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib 300 mg daily plus fulvestrant 500 mg
Study: 32147925
Drug: Water-soluble CBD
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble CBD powder (30 mg)
Study: 32147925
Drug: Lipid-soluble CBD
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-soluble CBD powder (30 mg)
Study: 32147925
Drug: CBD exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD exposure (both formulations)
Study: 34324113
Drug: Post-mastectomy radiation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-mastectomy radiation therapy (PMRT)
Study: 34307194
Drug: Adjunctive COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive COX-2 inhibitor (etoricoxib)
Study: 34307194
Drug: Standard TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TB treatment without COX-2 inhibitor
Study: 32114523
Drug: Drospirenone 4
Normalized name: drospirenone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 4 mg film-coated tablet, 24 days active treatment followed by 4 days placebo, for 13 cycles of 28 days each
Study: 36423240
Drug: PCC4 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCC4 (30 units/kg) administered intraoperatively
Study: 32348263
Drug: Pedometer app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pedometer app with structured information delivery, personalized physical activity prescription, and follow-up on number of steps per day
Study: 32348263
Drug: Pedometer app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pedometer app with daily walking goal of 10,000 steps
Study: 36112590
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin coconut oil (EVCO) 25 g
Study: 36112590
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVOO) 25 g
Study: 34075589
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg intravenous, weeks 0, 4, and 8)
Study: 34425071
Drug: Selonsertib 2
Normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib 2 mg
Study: 32147362
Drug: Selonsertib 6
Normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib 6 mg
Study: 32147362
Drug: Selonsertib 18
Normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib 18 mg
Study: 33982167
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using glass ionomer cement (KetacTM Molar Easymix)
Study: 33419872
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (PCV9)
Study: 33970042
Drug: CaneCPI-5 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaneCPI-5 (0.1 mg/mL)
Study: 32046669
Drug: Online intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online intervention based on Cognitive Behavioral Therapy (n=120)
Study: 33220397
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (AA) with FOLFOX x6 cycles prior to high dose rate brachytherapy (HDRBT) and surgery plus adjuvant FOLFOX x6 cycles
Study: 33499569
Drug: Fractional carbon
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional carbon dioxide laser combined with autologous fat injection
Study: 36214144
Drug: Basal analgesia:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal analgesia: midazolam (1 mg), fentanyl (0.05 mg), dexketoprofen (50 mg)
Study: 34022103
Drug: Lactobacilli (SynForU‐HerCare;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli (SynForU‐HerCare; two capsules/day of 9·5 log CFU per capsule)
Study: 35527324
Drug: Morphine-based patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-based patient-controlled analgesia (PCA)
Study: 33142467
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg SB
Study: 33142467
Drug: 600 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/kg SB
Study: 33142467
Drug: 1,200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg/kg SB
Study: 35786581
Drug: Preemptive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive group (n=50) - administered 600 mg of ibuprofen 1 hour before the procedure
Study: 35786581
Drug: Preventive group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive group (n=50) - administered placebo preoperatively
Study: 34133859
Drug: Targeted normothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted normothermia with early treatment of fever (body temperature, ≥37.8°C)
Study: 32430027
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) treatment, 1 to 3 treatment cycles
Study: 37045502
Drug: Genetic-guided P2Y12
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic-guided P2Y12 inhibitor therapy (ticagrelor for LOF carriers, clopidogrel for noncarriers)
Study: 37045502
Drug: Conventional clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional clopidogrel therapy
Study: 32497605
Drug: Oxygen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplementation (10 L/min) for long durations (≥75th percentile)
Study: 32497605
Drug: Oxygen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplementation (10 L/min) for short durations (<75th percentile)
Study: 35605429
Drug: PRI-724 (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRI-724 (280 mg/m2/4 h) administered intravenously twice weekly for 12 weeks
Study: 33631372
Drug: Cognitive Reserve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Reserve EnhAncement ThErapy (CREATE)
Study: 33631372
Drug: Community comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community comparison group (CC)
Study: 32472357
Drug: Ambrisentan 10
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 10 mg (generic product)
Study: 32472357
Drug: Volibris® (ambrisentan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volibris® (ambrisentan) 10 mg (reference product)
Study: 32472357
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Ambrisentan 10 mg and Volibris® 10 mg)
Study: 34363764
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 0.5% bupivacaine hydrochloride + 1 mL/4 mg dexamethasone (Group A1)
Study: 34363764
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine hydrochloride + 1 mL/4 mg dexamethasone (Group B1)
Study: 34363764
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 0.5% bupivacaine hydrochloride (Group A)
Study: 34011358
Drug: Artefenomel (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel (800 mg) plus ferroquine (400 mg to 1200 mg)
Study: 35510765
Drug: Hydroquinone 4%/ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinone 4%/ascorbic acid 3% cream (HC)
Study: 32106548
Drug: Standardized bilberry
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized bilberry extract (SBE) 240 mg once daily for 12 weeks